Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform.
In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine.
The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 24 | -0.21 Decreased by -50.00% | -0.13 Decreased by -61.54% |
| May 7, 24 | -0.15 Increased by 0.00% | -0.14 Decreased by -7.14% |
| Feb 29, 24 | -0.02 Decreased by -166.67% | -0.20 Increased by +90.00% |
| Nov 13, 23 | -0.18 Increased by +71.43% | -0.19 Increased by +5.26% |
| Aug 10, 23 | -0.14 Increased by +85.11% | -0.24 Increased by +41.67% |
| May 8, 23 | -0.15 Increased by +76.56% | -0.32 Increased by +53.13% |
| Mar 30, 23 | 0.03 Increased by +103.53% | -0.46 Increased by +106.52% |
| Nov 7, 22 | -0.63 Increased by +4.55% | -0.71 Increased by +11.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 18.46 M Decreased by -9.74% | -7.00 M Increased by +9.67% | Decreased by -37.91% Decreased by -0.08% |
| Jun 30, 24 | 22.80 M Increased by +9.86% | -9.25 M Decreased by -46.76% | Decreased by -40.57% Decreased by -33.59% |
| Mar 31, 24 | 19.93 M Decreased by -1.58% | -6.63 M Decreased by -30.06% | Decreased by -33.26% Decreased by -32.15% |
| Dec 31, 23 | 23.36 M Decreased by -25.71% | -988.00 K Decreased by -146.38% | Decreased by -4.23% Decreased by -231.64% |
| Sep 30, 23 | 20.45 M Increased by +63.15% | -7.75 M Increased by +73.32% | Decreased by -37.88% Increased by +83.65% |
| Jun 30, 23 | 20.75 M Increased by +92.19% | -6.30 M Increased by +85.11% | Decreased by -30.37% Increased by +92.25% |
| Mar 31, 23 | 20.25 M Increased by +93.12% | -5.10 M Increased by +82.08% | Decreased by -25.17% Increased by +90.72% |
| Dec 31, 22 | 31.45 M Increased by +227.64% | -401.00 K Increased by +98.91% | Decreased by -1.28% Increased by +99.67% |